Health Innovation
4 Health Startups Turning Grants Into Product Progress
DealBio tracks early-stage health and longevity startups across Europe and North America. These 4 are pairing non-dilutive funding with concrete product milestones.
- Non-Dilutive Funding
- Working Prototype
- Clinical Use
- B2B
For investors, grants become more informative when they leave something tangible behind: a prototype that works, a test that has been validated, a platform ready for pilots or a product already being used.
These four startups show that progression at different stages, from functional prototypes to live hospital deployments.
At a Glance
- Dental RoboticsSwitzerland2026Portable dental system and commercial LOIs
- Beyond DiagnosticsSwitzerland2026Functional insulin-activity prototype
- Constellate ProteomicsNetherlands2025Operational biopharma pilot platform
- enamentisGermany2024AI sterile-processing system live in hospitals
Building a portable 3-in-1 dental system for preventive care outside clinics.
- Country
Switzerland- Founded
- 2026
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why Dental Robotics stands out
Dental Robotics won CHF120,000 through the 2026 W.A. de Vigier Award and reached CHF50,000 in cumulative Venture Kick support. The important link to product progress is that the team has also completed functional 3D-printed models and signed a 100-unit LOI with Jet Dental plus a second US mobile-dental LOI.
What Dental Robotics is building
Claire is a portable dental setup combining suction, scaling, a micromotor and an intraoral camera with a chair, stool and tablet control. The system is designed for preventive care in homes, workplaces and care facilities without fixed dental plumbing.
Building smartphone-read point-of-care tests to verify insulin quality.
- Country
- Switzerland
- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
- Founders
Why Beyond Diagnostics stands out
Beyond Diagnostics is part of a CHF659,000 Innosuisse-supported R&D project with CSEM. That support sits alongside a clear product sequence: in-vitro assay validation in 2025 followed by a first functional insulin-activity prototype in February 2026.
What Beyond Diagnostics is building
LUMIQ is a smartphone-read lateral-flow test designed to estimate the biological activity remaining in insulin before injection. The product brings a medication-quality check closer to the point of use.
Building single-molecule tools to screen antibody quality earlier in development.
- Country
Netherlands- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Constellate Proteomics stands out
Constellate Proteomics has €535,000 in financing and public support behind the spinout, including Biotech Booster and Faculty of Impact funding. The product milestone is an operational TU Delft platform with validated titre and glycosylation probes and pilots open for biopharma and CDMO samples.
What Constellate Proteomics is building
RAYmAb is designed to measure antibody output and quality directly from crude culture samples. By moving glycosylation and other quality information earlier, Constellate aims to improve cell-line selection before weeks of growth and purification.
Building AI vision and robotics for hospital sterile-processing workflows.
- Country
Germany- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why enamentis stands out
More than €1 million in EXIST Research Transfer funding supported Cir.Log's move from Fraunhofer research to market. The clearest evidence of that conversion is deployment: Cir.Log is now live at three hospitals in Germany and Austria and integrates directly with NEXUS EuroSDS.
What enamentis is building
Cir.Log uses a retrofit camera and computer vision to recognise, count and document surgical instruments at sterile-processing packing tables. enamentis is extending the same AI layer into robotics for broader automation of repetitive reprocessing tasks.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
Non-dilutive funding becomes more informative after the startup can point to what changed because of it. In this group, that means moving from a concept toward working hardware, a validated assay, an operational pilot platform or hospital deployment.
For investors, that changes the diligence question from “what will this grant fund?” to “what did the team prove with it?” The second is easier to test. A smaller grant that unlocks a harder milestone can be more informative than a larger award that leaves the product at the same stage.
Methodology
DealBio selected these startups from its database of early-stage health and longevity startups, focusing on startups with meaningful non-dilutive funding and a visible product milestone. The selection spans medtech, diagnostics, biotech tools and hospital automation.
DealBio builds its Startup Briefs using publicly available company materials, ecosystem sources, market references and professional profiles.